Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

Abstract

Somatic retinoblastoma 1 (RB1) loss is prevalent across different cancer types and is enriched in treatment-refractory tumors, such as castration-resistant prostate cancer (CRPC) and small-cell lung cancer, but cannot be considered as a direct druggable target. In this study, we revealed that the close proximity of nudix hydrolase 15 (NUDT15) and RB1 may result in their common somatic codeletion or epigenomic cosilencing in different cancer types and subsequent significant positive correlations of their expressions at the bulk transcriptional and single-cell levels. With clinical CRPC samples, co-loss of RB1 and NUDT15 were commonly observed (14 out of 21). Due to the contribution of NUDT15 deficiency to thiopurine-induced toxicity, exploiting a vulnerability conferred by RB1–NUDT15 loss raised the possibility of repurposing thiopurine (e.g., mercaptopurine) for precise therapeutics. A positive relationship between RB1/NUDT15 ploidy score and mercaptopurine drug sensitivity was found in 543 cancer cell lines. Experimentally, knocking-down NUDT15 sensitizes the cancer cell lines to mercaptopurine treatment by inhibiting cell cycle progression and increasing apoptosis, but does not induce mercaptopurine-related leucopenia in xenograft model. Our study elucidates the molecular basis for precise mercaptopurine therapy in RB1-deficient tumors and demonstrates how leveraging collateral lethality alongside drug repurposing uncovers targetable vulnerabilities in stratified patient cohorts.

Keywords

collateral lethality / copy number deletion / drug repurposing / mercaptopurine / NUDT15 / RB1

References

[1] Y. Li, N. D. Roberts, J. A. Wala, et al., “Patterns of Somatic Structural Variation in human Cancer Genomes,” Nature 578, no. 7793 (2020): 112-121.

[2] G. R. Bignell, C. D. Greenman, H. Davies, et al., “Signatures of Mutation and Selection in the Cancer Genome,” Nature 463, no. 7283 (2010): 893-898.

[3] G. Xu, J. Zheng, S. Wang, et al., “Landscape of RB1 Alterations in 22,432 Chinese Solid Tumor Patients,” Annals of Translational Medicine 10, no. 16 (2022): 885.

[4] H. Z. Chen, S. Y. Tsai, and G. Leone, “Emerging Roles of E2Fs in Cancer: An Exit From Cell Cycle Control,” Nature Reviews Cancer 9, no. 11 (2009): 785-797.

[5] M. Peifer, L. Fernández-Cuesta, M. L. Sos, et al., “Integrative Genome Analyses Identify Key Somatic Driver Mutations of Small-cell Lung Cancer,” Nature Genetics 44, no. 10 (2012): 1104-1110.

[6] D. C. Wedge, G. Gundem, T. Mitchell, et al., “Sequencing of Prostate Cancers Identifies New Cancer Genes, Routes of Progression and Drug Targets,” Nature Genetics 50, no. 5 (2018): 682-692.

[7] C. S. Grasso, Y. M. Wu, D. R. Robinson, et al., “The Mutational Landscape of Lethal Castration-resistant Prostate Cancer,” Nature 487, no. 7406 (2012): 239-243.

[8] H. Beltran, D. Prandi, J. M. Mosquera, et al., “Divergent Clonal Evolution of Castration-resistant Neuroendocrine Prostate Cancer,” Nature Medicine 22, no. 3 (2016): 298-305.

[9] W. Abida, J. Cyrta, and G. Heller, “Genomic Correlates of Clinical Outcome in Advanced Prostate Cancer,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 23 (2019): 11428-11436.

[10] W. S. Chen, R. Aggarwal, and L. Zhang, “Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer,” European Urology 76, no. 5 (2019): 562-571.

[11] F. Tang, D. Xu, and S. Wang, “Chromatin Profiles Classify Castration-resistant Prostate Cancers Suggesting Therapeutic Targets,” Science (New York, NY) 376, no. 6596 (2022): eabe1505.

[12] F. Saad, A. Thiery-Vuillemin, P. Wiechno, et al., “Patient-reported Outcomes With Olaparib plus Abiraterone versus Placebo plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: A Randomised, Double-blind, Phase 2 Trial,” The Lancet Oncology 23, no. 10 (2022): 1297-1307.

[13] O. Sartor, J. de Bono, K. N. Chi, et al., “Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer,” The New England Journal of Medicine 385, no. 12 (2021): 1091-1103.

[14] R. Garje, R. B. Rumble, and R. A. Parikh, “Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology (2022): Jco2201865.

[15] W. Han, M. Liu, D. Han, et al., “RB1 loss in Castration-resistant Prostate Cancer Confers Vulnerability to LSD1 Inhibition,” Oncogene 41, no. 6 (2022): 852-864.

[16] E. S. Knudsen, S. C. Pruitt, P. A. Hershberger, A. K. Witkiewicz, and D. W. Goodrich, “Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy,” Trends in Cancer 5, no. 5 (2019): 308-324.

[17] P. Linn, S. Kohno, J. Sheng, et al., “Targeting RB1 Loss in Cancers,” Cancers 13, no. 15 (2021): 3737.

[18] F. L. Muller, E. A. Aquilanti, and R. A. DePinho, “Collateral Lethality: A New Therapeutic Strategy in Oncology,” Trends in Cancer 1, no. 3 (2015): 161-173.

[19] P. Dey, J. Baddour, F. Muller, et al., “Genomic Deletion of Malic Enzyme 2 Confers Collateral Lethality in Pancreatic Cancer,” Nature 542, no. 7639 (2017): 119-123.

[20] Z. Zhao, L. Zhu, Y. Luo H. Xu, and Y. Zhang, “Collateral Lethality: A Unique Type of Synthetic Lethality in Cancers,” Pharmacology & Therapeutics 265 (2025): 108755.

[21] F. L. Muller, S. Colla, E. Aquilanti, et al., “Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer,” Nature 488, no. 7411 (2012): 337-342.

[22] G. V. Kryukov, F. H. Wilson, and J. R. Ruth, “MTAP Deletion Confers Enhanced Dependency on the PRMT5 Arginine Methyltransferase in Cancer Cells,” Science 351, no. 6278 (2016): 1214-1218.

[23] S. Kohno, P. Linn, N. Nagatani, et al., “Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion,” Oncogene 39, no. 34 (2020): 5690-5707.

[24] T. Moriyama, R. Nishii, V. Perez-Andreu, et al., “NUDT15 polymorphisms Alter Thiopurine Metabolism and Hematopoietic Toxicity,” Nature Genetics 48, no. 4 (2016): 367-373.

[25] Y. Zhu, D. Yin, and Y. Su, “Combination of Common and Novel Rare NUDT15 Variants Improves Predictive Sensitivity of Thiopurine-induced Leukopenia in Children With Acute Lymphoblastic Leukemia,” Haematologica 103, no. 7 (2018): e293-e295.

[26] R. Nishii, T. Moriyama, and L. J. Janke, “Preclinical Evaluation of NUDT15-guided Thiopurine Therapy and Its Effects on Toxicity and Antileukemic Efficacy,” Blood 131, no. 22 (2018): 2466-2474.

[27] M. V. Relling, M. Schwab, M. Whirl-Carrillo, et al., “Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update,” Clinical Pharmacology & Therapeutics 105, no. 5 (2019): 1095-1105.

[28] T. Chen, P. H. O'Donnell, M. Middlestadt, et al., “Implementation of Pharmacogenomics Into Inpatient General Medicine,” Pharmacogenet Genomics 33, no. 2 (2023): 19-23.

[29] H. Song, H. N. W. Weinstein, P. Allegakoen, et al., “Single-cell Analysis of human Primary Prostate Cancer Reveals the Heterogeneity of Tumor-associated Epithelial Cell States,” Nature Communications 13, no. 1 (2022): 141.

[30] A. Yim, C. Smith, and A. M. Brown, “Osteopontin/Secreted Phosphoprotein-1 Harnesses Glial-, Immune-, and Neuronal Cell Ligand-receptor Interactions to Sense and Regulate Acute and Chronic Neuroinflammation,” Immunological Reviews 311, no. 1 (2022): 224-233.

[31] P. Zeng, X. Zhang, T. Xiang, Z. Ling, C. Lin, and H. Diao, “Secreted Phosphoprotein 1 as a Potential Prognostic and Immunotherapy Biomarker in Multiple human Cancers,” Bioengineered 13, no. 2 (2022): 3221-3239.

[32] H. Luo, X. Xia, and L. B. Huang, “Pan-cancer Single-cell Analysis Reveals the Heterogeneity and Plasticity of Cancer-associated Fibroblasts in the Tumor Microenvironment,” Nature Communications 13, no. 1 (2022): 6619.

[33] L. N. Toksvang, S. H. R. Lee, J. J. Yang, and K. Schmiegelow, “Maintenance Therapy for Acute Lymphoblastic Leukemia: Basic Science and Clinical Translations,” Leukemia 36, no. 7 (2022): 1749-1758.

[34] J. Zhou, Z. Wu, Z. Zhang, et al., “Pan-ERBB Kinase Inhibition Augments CDK4/6 Inhibitor Efficacy in Oesophageal Squamous Cell Carcinoma,” Gut 71, no. 4 (2022): 665-675.

[35] J. Bollard, V. Miguela, M. Ruiz de Galarreta, et al., “Palbociclib (PD-0332991), a Selective CDK4/6 Inhibitor, Restricts Tumour Growth in Preclinical Models of Hepatocellular Carcinoma,” Gut 66, no. 7 (2017): 1286-1296.

[36] A. T. Ghanbarian and L. D. Hurst, “Neighboring Genes Show Correlated Evolution in Gene Expression,” Molecular Biology and Evolution 32, no. 7 (2015): 1748-1766.

[37] J. A. Beagan and J. E. Phillips-Cremins, “On the Existence and Functionality of Topologically Associating Domains,” Nature Genetics 52, no. 1 (2020): 8-16.

[38] H. Xu, X. Zhao, and D. Bhojwani, “ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 26, no. 1 (2020): 256-264.

[39] T. A. Ahmed, E. M. M. Ali, A. A. Kalantan, A. M. Almehmady, and K. M. El-Say, “Exploring the Enhanced Antiproliferative Activity of Turmeric Oil and 6-Mercaptopurine in a Combined Nano-Particulate System Formulation,” Pharmaceutics 15, no. 7 (2023): 1901.

[40] G. P. Kumar, J. S. Sanganal, A. R. Phani, et al., “Anti-cancerous Efficacy and Pharmacokinetics of 6-mercaptopurine Loaded Chitosan Nanoparticles,” Pharmacological Research 100 (2015): 47-57.

[41] M. Ge, J. Luo, Y. Wu, G. Shen, and X. Kuang, “The Biological Essence of Synthetic Lethality: Bringing New Opportunities for Cancer Therapy,” MedComm-Oncology 3, no. 1 (2024): e70.

[42] L. J. Schipper, L. J. Zeverijn, M. J. Garnett, and E. E. Voest, “Can Drug Repurposing Accelerate Precision Oncology?,” Cancer Discovery 12, no. 7 (2022): 1634-1641.

[43] D. M. Girardi, A. C. B. Silva, J. F. M. Rêgo, R. A. Coudry, and R. P. Riechelmann, “Unraveling Molecular Pathways of Poorly Differentiated Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Systematic Review,” Cancer Treatment Reviews 56 (2017): 28-35.

[44] A. F. Gazdar, P. A. Bunn, and J. D. Minna, “Small-cell Lung Cancer: What We Know, What We Need to Know and the Path Forward,” Nature Reviews Cancer 17, no. 12 (2017): 725-737.

[45] M. J. Niederst, L. V. Sequist, J. T. Poirier, et al., “RB Loss in Resistant EGFR Mutant Lung Adenocarcinomas That Transform to Small-cell Lung Cancer,” Nature Communications 6 (2015): 6377.

[46] W. Du and J. Pogoriler, “Retinoblastoma family Genes,” Oncogene 25, no. 38 (2006): 5190-5200.

[47] X. Gong, J. Du, S. H. Parsons, et al., “Aurora A Kinase Inhibition Is Synthetic Lethal With Loss of the RB1 Tumor Suppressor Gene,” Cancer Discovery 9, no. 2 (2019): 248-263.

[48] M. G. Oser, R. Fonseca, and A. A. Chakraborty, “Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival,” Cancer Discovery 9, no. 2 (2019): 230-247.

[49] A. K. Witkiewicz, S. Chung, R. Brough, et al., “Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer,” Cell Reports 22, no. 5 (2018): 1185-1199.

[50] R. Brough, A. Gulati, and S. Haider, “Identification of Highly Penetrant Rb-related Synthetic Lethal Interactions in Triple Negative Breast Cancer,” Oncogene 37, no. 43 (2018): 5701-5718.

[51] J. C. Massey, J. Magagnoli, S. S. Sutton, P. J. Buckhaults, and M. D. Wyatt, “Collateral Damage of NUDT15 Deficiency in Cancer Provides a Cancer Pharmacogenetic Therapeutic Window With Thiopurines,” BioRxiv (2024).

[52] J. Meng, Y. Zhou, X. Lu, et al., “Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy,” Molecular Oncology 15, no. 5 (2021): 1358-1375.

[53] H. Luo, X. Xia, G. D. Kim, et al., “Characterizing Dedifferentiation of Thyroid Cancer by Integrated Analysis,” Science Advances 7, no. 31 (2021): eabf3657.

[54] M. Cao, Y. Deng, Y. Deng, et al., “Characterization of Immature Ovarian Teratomas Through Single-cell Transcriptome,” Frontiers in Immunology 14 (2023): 1131814.

[55] T. Zhou, H. Yan, and Y. Deng, “The Role of Long Non-coding RNA Maternally Expressed Gene 3 in Cancer-associated Fibroblasts at Single Cell Pan-cancer Level,” Interdisciplinary Medicine (2024): e20240018.

[56] X. Xia, C. He, Z. Xue, et al., “Single Cell Immunoprofile of Synovial Fluid in Rheumatoid Arthritis With TNF/JAK Inhibitor Treatment,” Nature Communications 16, no. 1 (2025): 2152.

[57] M. Cao, Y. Deng, Q. Hao, et al., “Single-cell Transcriptomic Analysis Reveals Gut Microbiota-immunotherapy Synergy Through Modulating Tumor Microenvironment,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 140.

[58] W. Mao, T. Zhou, and F. Zhang, “Pan-cancer Single-cell Landscape of Drug-metabolizing Enzyme Genes,” Pharmacogenet Genomics 34, no. 7 (2024): 217-225.

[59] H. Xu, H. Zhang, W. Yang, et al., “Inherited Coding Variants at the CDKN2A Locus Influence Susceptibility to Acute Lymphoblastic Leukaemia in Children,” Nature Communications 6 (2015): 7553.

[60] Y. Shu, W. Zhang, Q. Hou, et al., “Prognostic Significance of Frequent CLDN18-ARHGAP26/6 Fusion in Gastric Signet-ring Cell Cancer,” Nature Communications 9, no. 1 (2018): 2447.

[61] X. Liao, X. Xia, W. Su, et al., “Association of Recurrent APOBEC3B Alterations With the Prognosis of Gastric-type Cervical Adenocarcinoma,” Gynecologic Oncology 165, no. 1 (2022): 105-113.

[62] X. Guo, F. Chen, F. Gao, et al., “CNSA: A Data Repository for Archiving Omics Data,” Database (Oxford) 2020 (2020): baaa055.

[63] F. Z. Chen, L. J. You, F. Yang, et al., “CNGBdb: China National GeneBank DataBase,” Yi Chuan 42, no. 8 (2020): 799-809.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.